

"Diabegon", a safe and effective polyherbal therapy for type 2 diabetes mellitus

Sunil Mahajan, Nita Singh, Senthil K Subramanian, Pratibha Chauhan, Sonali Saxena, HM Goswamy, GBKS Prasad, Prakash S Bisen

Sunil Mahajan, Nita Singh, Senthil K Subramanian, Pratibha Chauhan, Sonali Saxena, HM Goswamy, GBKS Prasad, School of Studies in Biochemistry, Jiwaji University, Gwalior 474011, India

Prakash S Bisen, School of Studies in Biotechnology, Jiwaji University, Gwalior 474011, India

Author contributions: Mahajan S, Singh N and Chauhan P were involved in the experimental work; Subramanian SK and Saxena S were associated with the registration, follow up and collection of blood specimens, etc.; Goswamy HM contributed to supervision of the drugs administered; Prasad GBKS and Bisen PS were associated with the study design, execution and manuscript preparation.

Supported by AYUSH, New Delhi, India, No. F.NO. Z.31014/02/2009/EMR-CCARS; and M/S Deendayal Aushadhi Pvt. Ltd. Gwalior, India

Correspondence to: Prakash S Bisen, Professor, School of Studies in Biotechnology, Jiwaji University, Mahalgaon, Gwalior 474 011, India. psbisen@gmail.com

Telephone: +91-751-2462500 Fax: +91-751-4043850

Received: August 25, 2013 Revised: October 21, 2013

Accepted: November 20, 2013

Published online: December 12, 2013

Abstract

AIM: To investigate the antihyperglycemic, antihyperlipidemic and antioxidant functions of a polyherbal formulation, "Diabegon", in human subjects with type 2 diabetes mellitus.

METHODS: A total of 33 human subjects with type 2 diabetes mellitus were recruited for the study and all anthropological and biochemical parameters were recorded at the time of registration. The subjects were given hot water extract obtained from 10 gm of "Diabegon" powder, "Diabegon kwath", on an empty stomach everyday in the morning under personal supervision for 6 mo. The therapeutic functions of the "Diabegon kwath" was assessed by monitoring the blood glucose

levels at monthly intervals and glycosylated hemoglobin, lipid profile and biomarkers of oxidative stress, liver and kidney function markers at three monthly intervals in the study subjects.

RESULTS: Daily administration of hot water extract of "Diabegon" regularly for 6 mo resulted in significant reductions of blood glucose and glycosylated hemoglobin levels. There was also a significant increase in high density lipoprotein cholesterol levels with concomitant decreases in total cholesterol, triglycerides, low density lipoprotein cholesterol and very low density lipoprotein. A significant improvement in glycosuria and proteinuria was also observed. Also, the subjects exhibited a significant improvement in enzymatic and nonenzymatic biochemical markers of oxidative stress. The kidney and liver functions remained normal and in fact improved in many subjects.

CONCLUSION: The study which is first of its kind, advocates "Diabegon kwath" as a safe and effective Ayurvedic therapy for the treatment of human type 2 diabetes mellitus and further placebo controlled trial may substantiate the therapeutic efficacy of the formulation.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Type 2 diabetes mellitus; Diabegon kwath; Polyherbal formulation; Oxidative stress; Blood glucose; Lipids; Antihyperglycemic; Antihyperlipidemic; Antioxidant; antidiabetic therapies

Core tip: The study evaluated antihyperglycemic, antihyperlipidemic and antioxidant functions of a polyherbal formulation designated "Diabegon kwath" in type 2 diabetic subjects with varying degrees of hyperglycemia and found that the formulation serves as an effective alternative to conventional antidiabetic therapies.

Mahajan S, Singh N, Subramanian SK, Chauhan P, Saxena S, Goswamy HM, Prasad GBKS, Bisen PS. "Diabegon", a safe and effective polyherbal therapy for type 2 diabetes mellitus. *World J Transl Med* 2013; 2(3): 75-82 Available from: URL: <http://www.wjgnet.com/2220-6132/full/v2/i3/75.htm> DOI: <http://dx.doi.org/10.5528/wjtm.v2.i3.75>

INTRODUCTION

Type 2 diabetes mellitus is one of the most common global metabolic disorders and is characterized by abnormalities of carbohydrate and lipid metabolisms, mainly resulting either from defects in insulin secretion and/or insulin action, or adipocyte functioning^[1]. Although the disease manifests in the form of hyperglycemia, the cause can vary, ranging from disturbance in insulin secretion, insulin action, insulin resistance, glucose production and glucose uptake, interplay among different metabolic pathways, hormones, *etc.* Type II diabetic patients often exhibit increased low density lipoprotein (LDL) and decreased high density lipoprotein (HDL) cholesterol levels and hypertension, as well as altered platelet function^[2]. Due to such varied etiology, not a single agent or molecule has so far been unequivocally accepted as the antidiabetic drug. There is a broad range of glucose and lipid-lowering (metformin, sulfonylureas, insulin, statins) drugs which although are successful to some extent, careful consideration must be given when selecting the appropriate glucose and lipid-lowering therapy. The conventional antidiabetic therapies are reported to be associated with many side effects, such as hypoglycemia, lactic acid intoxication and gastrointestinal upset^[3], in diabetic subjects. Statins are very widely used during dyslipidemia and there are reports in experimental models that statin therapy may exhibit an adverse effect on glucose homeostasis^[4].

Indigenous systems of medicine based on traditional wisdom have thrived through the ages and are practiced by a large population all over the globe for the management of diabetes. A large number of plants have proved their efficacy in the management of hyperglycemia, hyperlipidemia, oxidative stress and the inflammatory response^[5-7]. Scientific validation of many of the plant-based antidiabetic medicines has been done^[8-10] and the bioactive principles identified and characterized^[11,12]. The antihyperglycemic effect of several plant extracts and herbal formulations that are used as antidiabetic remedies has been confirmed^[13,14]. Plant drugs are frequently considered to be less toxic and free from side effects than synthetic ones^[15]. Combined extracts of herbs are used as the drug of choice rather than individual plant extracts. Herbal formulations^[16] were shown to exhibit antidiabetic, antioxidant effects in animal models as well as in diabetic subjects^[17,18]. The phytochemical based formulations consist of multiple herbs and are therefore liable to produce a large number of metabolites that may act on multiple targets in the body. Although the phytochemical formulations have been widely used for many years,

systematic scientific evidence and proof of efficacy are generally lacking compared with synthesized chemical medicines. Diabegon powder, a plant based formulation consisting of a mixture of about 10 herbs, *Gymnema sylvestre* (*Gurmar*), *Eugenia jambolana* (*Jamun seed*), *Emblica officianale* (*Amla*), *Curcuma longa* (*Haldi*), *Pterocarpus marsupium* (*Vijaysaar*), *Terminalia chebula* (*Harad*), *Cassia fistula* (*Amaltas*), *Picrorhiza kurroa* (*Kutki*), *Swertia charita* (*Chiraita*) and *Terminalia Bellerica* (*Behada*), was validated in this study for its therapeutic potential in human type II diabetes mellitus.

MATERIALS AND METHODS

Subjects

A total of 33 type II diabetic subjects attending a weekend diabetes clinic run by the School of Studies in Biochemistry, Jiwaji University, India were randomly selected for the study after giving informed written consent. The following criteria were employed for selecting the subjects for the study.

Inclusion criteria

1. Non-insulin dependent diabetics diagnosed as per the criteria of World Health Organization;
2. Both genders between the ages of 30-65 years;
3. Body Mass Index range between 18.5 and 30;
4. Participants who understood the benefits of the study and signed a written informed consent.

Exclusion criteria

1. Presently using other blood glucose level controlling agents;
2. Daily intake of alcoholic beverages;
3. Smokers consuming more than 1 pack/d;
4. Patients diagnosed as type I and type II diabetes mellitus (insulin requiring stage);
5. Patients with ketosis, diabetes related complications, hepatic or renal disease, pancreatitis, cardiac problems, uncontrolled hypertension, malnutrition and severe immune deficiency.

The subjects had the objectives, nature of drugs, rationale and duration of therapy to be administered explained to them in the local language. They were asked to avoid a carbohydrate rich diet and regular walking for about 4-5 km during the course of therapy was advocated. Anthropometric measurements like weight, height and waist were recorded at monthly intervals. The patients were kept exclusively on "Diabegon therapy" and did not take any other kind of oral antihyperglycemic or lipid lowering drugs during the study period.

Drug, doses and duration

The drug administered is purely a polyherbal formulation consisting of *Gymnema sylvestre* (*Gurmar*), *Eugenia jambolana* (*Jamun seed*), *Emblica officianale* (*Amla*), *Curcuma longa* (*Haldi*), *Pterocarpus marsupium* (*Vijaysaar*), *Terminalia chebula* (*Harad*), *Cassia fistula* (*Amaltas*), *Picrorhiza kurroa* (*Kutki*), *Swertia charita* (*Chiraita*) and *Terminalia bellerica* (*Behada*)

Table 1 Effect of 6 mo polyherbal therapy on hyperglycemia

Biochemical parameter	Variations at 3 monthly intervals following polyherbal therapy			
	0 d	3 mo	6 mo	Mean change
Fasting plasma glucose (mg/dL)	159.54 ± 7.74	130.08 ± 6.58 ^b	131.02 ± 3.63 ^b	(↓ 17.8%)
Postprandial glucose (mg/dL)	248.30 ± 11.82	196.48 ± 11.23 ^b	183.54 ± 10.54 ^b	(↓ 26.0%)
HbA1c (%)	7.22 ± 0.14	6.65 ± 0.14 ^b	6.41 ± 0.11 ^b	(↓ 11.2%)

Data are expressed as mean ± SEM; ^b*P* < 0.001 compared to 0th d levels.

and was provided by M/S Deendayal Aushadhi Pvt. Ltd., India. Each subject had 50 mL of fresh hot water extract derived from 10 gm of "Diabegon" powder soaked overnight in water administered daily on an empty stomach and therapy continued for six months without any break under the supervision of an Ayurvedic physician. The study design was approved by the Institutional Human Ethics Committee of Jiwaji University.

Biochemical parameters

The fasting and postprandial plasma glucose measurements were determined at monthly intervals, while the glycosylated hemoglobin, antioxidant parameters such as super oxide dismutase, catalase, glutathione (GSH), Thio-barbituric Acid Reactive Substances (TBARS) and lipid profile, functional markers of kidney and liver function were monitored at baseline, at the middle (3 mo) and at the end (6 mo) of the therapy.

Fasting and postprandial plasma glucose was estimated by the Glucose oxidase/Peroxidase method^[19]. Glycosylated hemoglobin (HbA1c) was estimated by the ion exchange resin method^[20]. Estimation of plasma total cholesterol by the Cholesterol oxidase - Phenol-aminophenazone (CHOD-PAP) method^[21], triglyceride by the GPO-PAP method^[22], HDL by the Polyethylene glycol/ Cholesterol oxidase-Phenol-aminophenazone Polyethylene glycol/CHOD-PAP method^[23], LDL and VLDL were calculated by the Friedewald formula, urea by the modified Berthelot method^[24], uric acid by the uricase/PAP method^[25], creatinine by modified Jaffe's kinetic method^[26], serum glutamate pyruvate transaminase (SGPT or alanine transaminase) and serum glutamate oxaloacetate transaminase (SGOT or AST) by the modified International Federation of Clinical Chemistry method^[27] and bilirubin^[28] was assayed using standard kits from Crest Biosystems, Goa (India). Superoxide dismutase and catalase activities were assayed by Winterbourn *et al.*^[29] and by Sinha *et al.*^[30] respectively. Estimation of reduced GSH and TBARS was done by the method of Ellman^[31] and Ohkawa *et al.*^[32] respectively, and protein was estimated by the method of Lowry *et al.*^[33], estimation of urinary sugar by Benedict's method^[34] and urinary protein by the sulfo-salicylic method^[35].

Ethical clearance

The study protocol was duly approved by the Institution-

Table 2 Effect of 6 mo polyherbal therapy on lipidemia

Biochemical parameter	Variations at 3 monthly intervals following polyherbal therapy			
	0 d	3 mo	6 mo	Mean change
Total cholesterol (mg/dL)	162.08 ± 6.00	144.84 ± 5.20 ^b	146.8 ± 4.70 ^a	(↓ 9.4%)
Triglyceride (mg/dL)	140.81 ± 6.88	126.74 ± 6.88	122.3 ± 4.50 ^a	(↓ 13.1%)
HDL cholesterol (mg/dL)	34.38 ± 1.37	35.28 ± 1.04	37.9 ± 1.20 ^a	(↑ 9.8%)
LDL cholesterol (mg/dL)	99.33 ± 5.61	84.21 ± 5.21 ^b	81.98 ± 4.84 ^a	(↓ 17.4%)
VLDL (mg/dL)	28.16 ± 1.37	25.35 ± 1.37	23.71 ± 1.13 ^a	(↓ 15.8%)

Data are expressed as mean ± SEM; ^a*P* < 0.05, ^b*P* < 0.001 compared to 0th d levels. HDL: High density lipoprotein; LDL: Low density lipoprotein; VLDL: Very low density lipoprotein.

al Human Ethics Committee (JU/IHEC/2013-A/10).

Statistical analysis

Statistical analysis was done by a paired *t* test (Sigma stat 3.5).

RESULTS

Effect of polyherbal therapy on blood glucose levels

Table 1 shows the fasting and postprandial blood glucose levels at 3 monthly intervals following polyherbal therapy. A significant decrease (*P* < 0.001) was recorded in both fasting and postprandial glucose levels (17.8% and 26% respectively) and glycosylated hemoglobin (11.2%) at the end of six months therapy.

Effect of polyherbal therapy on lipidemia

Table 2 shows the results of the lipid profile. Total cholesterol, triglycerides, LDL and VLDL significantly decreased by 9.4%, 13.1%, 17.4%, 15.8% respectively (*P* < 0.05). HDL cholesterol significantly increased from 34.38 ± 1.37 to 37.78 ± 1.26 (*P* < 0.05) at the end of the therapy.

Effect of polyherbal therapy on biomarkers of oxidative stress

Significant (*P* < 0.05), improvements in GSH level (from 2.29 ± 0.26 to 3.03 ± 0.12 mg/dL), SOD activity (from 0.47 ± 0.07 to 0.74 ± 0.04 μmol/L min⁻¹ per mg protein), catalase activity (from 4.19 ± 0.37 to 6.07 ± 0.23 μmol/L min⁻¹ per milligram protein) and levels of TBARS (from 486.62 ± 29.82 to 442.26 ± 21.44 (moles of Malondialdehyde/mL of blood) were recorded at the end of polyherbal therapy (Table 3).

Effect of polyherbal therapy on biomarkers of toxicity

The effect of polyherbal therapy on kidney function was monitored by estimating urea, creatinine and uric acid levels in plasma at various intervals during the course of therapy. The data presented in Table 4 showed significant reductions in uric acid (from 5.35 ± 0.21 to 4.80 ± 0.97 mg/dL) and creatinine (from 0.78 ± 0.04 to 0.60 ± 0.02 mg/dL) and there was no significant change in the level

Table 3 Effect of 6 mo polyherbal therapy on biomarkers of oxidative stress

Biochemical parameter	Variations at 3 monthly intervals following polyherbal therapy			
	0 d	3 mo	6 mo	Mean change
GSH (mg/mL)	2.29 ± 0.26	2.74 ± 0.14	3.03 ± 0.12 ^a	(↑ 32.3%)
SOD (µmol/L · min ⁻¹ per milligram protein)	0.47 ± 0.07	0.58 ± 0.03	0.74 ± 0.04 ^a	(↑ 57.4%)
Catalase (µmol/L · min ⁻¹ per milligram protein)	4.19 ± 0.37	4.70 ± 0.27	6.07 ± 0.23 ^b	(↑ 44.8%)
TBARS (<i>n</i> moles of MDA/mL of blood)	486.62 ± 29.82	455.11 ± 21.81 ^a	442.26 ± 21.44 ^a	(↓ 9.1%)

Data are expressed as mean ± SEM; ^a*P* < 0.05 compared to 0th d levels. GSH: Glutathione; SOD: Superoxide dismutase; TBARS: Thiobarbituric acid reactive substances; MDA: Malondialdehyde.

Table 4 Effect of 6 mo polyherbal therapy on biochemical markers of kidney function

Biochemical parameter	Variations at 3 monthly intervals following polyherbal therapy			
	0 d	3 mo	6 mo	Mean change
Urea (mg/dL)	26.31 ± 0.97	26.45 ± 0.90	25.48 ± 0.87	(↓ 3.1%)
Uric acid (mg/dL)	5.35 ± 0.21	5.36 ± 0.16	4.80 ± 0.97 ^a	(↓ 10.2%)
Creatinine (mg/dL)	0.78 ± 0.04	0.76 ± 0.02	0.60 ± 0.02 ^b	(↓ 23.0%)

Data are expressed as mean ± SEM; ^a*P* < 0.05, ^b*P* < 0.001 compared to 0th d levels.

of urea.

Significant variations in enzyme markers of liver, namely SGOT (from 24.00 ± 3.04 to 21.49 ± 1.67 IU/L) and SGPT (from 25.33 ± 3.27 to 21.83 ± 64 IU/L), were recorded (Table 5). There was no change in the level of bilirubin.

Effect of polyherbal therapy on hypertension and body mass index

Table 6 shows variations in systolic blood pressure (130.40 ± 2.27 to 126.12 to 2.41 mmHg), diastolic blood pressure (81.06 ± 1.14 to 77.90 ± 1.35 mmHg) and body mass index (from 25.75 ± 0.57 to 24.85 ± 0.50 kg/m²).

Effect of polyherbal therapy on glycosuria and proteinuria

There were significant reductions in urinary sugar (64%) and urinary protein levels (60%) (Table 7) following polyherbal therapy.

DISCUSSION

The majority of the formulations used in Ayurveda are based on herbs and used as decoctions, infusion, tinctures and powders. The decoction of polyherbal formula-

Table 5 Effect of 6 mo polyherbal therapy on biochemical markers of liver function

Biochemical parameter	Variations at 3 monthly intervals following polyherbal therapy			
	0 d	3 mo	6 mo	Mean change
Total bilirubin (mg/dL)	0.98 ± 0.05	0.91 ± 0.06	0.97 ± 0.04	(↓ 1.0%)
SGOT (IU/L)	24.00 ± 3.04	21.70 ± 2.04 ^a	21.49 ± 1.67 ^a	(↓ 10.4%)
SGPT (IU/L)	25.33 ± 3.27	22.70 ± 2.24 ^a	21.83 ± 1.64 ^a	(↓ 13.8%)

Data are expressed as mean ± SEM; ^a*P* < 0.05 compared to 0th d levels. SGOT: Serum glutamate oxaloacetate transaminase; SGPT: serum glutamate pyruvate transaminase.

Table 6 Effect of 6 mo polyherbal therapy on blood pressure and anthropometry

Parameter	Variations at 3 monthly intervals following polyherbal therapy			
	0 d	3 mo	6 mo	Mean change
Systolic blood pressure (mmHg)	130.40 ± 2.27	125.15 ± 2.09 ^a	126.12 ± 2.41 ^a	(↓ 3.2%)
Diastolic blood pressure (mmHg)	81.06 ± 1.14	78.97 ± 1.23	77.90 ± 1.35	(↓ 3.8%)
Body mass index (kg/m ²)	25.75 ± 0.57	25.19 ± 0.56 ^b	24.85 ± 0.50 ^b	(↓ 3.4%)

Data are expressed as mean ± SEM; ^a*P* < 0.05, ^b*P* < 0.001 compared to 0th d levels.

Table 7 Effect of 6 mo polyherbal therapy on glycosuria and proteinuria

Parameter	Variations at 3 monthly intervals following polyherbal therapy			
	0 d	3 mo	6 mo	Mean change
Urinary sugar (gm/dL)	0.74 ± 0.10	0.34 ± 0.06 ^b	0.27 ± 0.06 ^b	(↓ 63.5%)
Urinary protein (mg/dL)	63.33 ± 16.68	43.63 ± 15.15	25.45 ± 6.50 ^a	(↓ 59.8%)

Data are expressed as mean ± SEM; ^a*P* < 0.05, ^b*P* < 0.001 compared to 0th d levels.

tion used in the present study (named "Diabegon kwath" in Ayurvedic terminology) contained hot water extract of powdered plant parts of *Gymnema sylvestre* (*Gurmar*), *Eugenia jambolana* (*Jamun seed*), *Emblica officianale* (*Amla*), *Curcuma longa* (*Haldi*), *Pterocarpus marsupium* (*Vijaysaar*), *Terminalia chebula* (*Harad*), *Cassia fistula* (*Amaltas*), *Picrorhiza kurroa* (*Kutki*), *Swertia charita* (*Chiraita*) and *Terminalia bellerica* (*Bebada*) in varying amounts. Administration of "Diabegon kwath" over a period of 6 months to type II diabetic subjects with varying degrees of hyperglycemia and hyperlipidemia resulted in significant alleviation of these metabolic abnormalities. Marked improvements in glucose homeostasis, as evident from significant changes in glycosylated hemoglobin and blood glucose levels, and lipid profile, as evident from elevations in HDL chole-

terol with concomitant decreases in other lipids, were observed. One of the major ingredients of the polyherbal preparation studied is *Gymnema Sylvestre* which is reported to promote insulin secretion, probably by regeneration of pancreatic beta cells^[36]. *In vitro* trials on experimental models with *Gymnema Sylvestre* have proved that this herbal drug increases insulin release by increasing the cell permeability^[37]. The *G. sylvestre* is reported to inhibit absorption of glucose from intestine. The leaves of *G. sylvestre* contain gymnemic acid and the atomic arrangement of gymnemic acid molecules is similar to that of glucose molecules. Gymnemic acid molecules fill the receptor location in the absorptive external layers of the intestine, thereby preventing the sugar molecules absorption by the intestine, which ultimately results in low blood sugar level^[38]. *Pterocarpus marsupium* is effective in reducing levels of blood glucose and glycosylated hemoglobin in type 2 diabetic patients^[39]. Alcoholic extract of *Picrorrhiza kurroa* (75 mg extract/kg) reduced serum glucose that was at a maximum 2 h after the dose. It also showed an antihyperglycemic effect in alloxanized diabetic rats. Serum glucose decreased by 43% and 60% with 75 and 150 mg/kg of the extracts, respectively. Antioxidant activity is also described in the literature^[40]. Hexane fraction of *Swertia chirayita* at 250 mg/kg, *po* to normal rats significantly reduced blood sugar and increased plasma insulin without influencing hepatic glycogen content. However, when administered for 28 d, it significantly increased hepatic glycogen content in conjunction with other effects, probably by releasing insulin^[41]. Decoction of stem bark of *Cassia fistula* Linn. improved glucose tolerance, significantly inhibited the glucose absorption from the small intestine and provoked glycogen accumulation in liver and skeletal muscle^[42,43]. *Terminalia chebula* exhibited *in vitro* antioxidant and free radical-scavenging activities^[44]. The antihyperglycemic effect of *T. chebula* is due to its ability to restore the functions of pancreatic tissues by causing an increase in insulin output, inhibiting the intestinal absorption of glucose or facilitating the metabolites in insulin dependent processes. In India, decoction of kernels of *Eugenia jambolana* is used as household remedy for diabetes. The antihyperglycemic effect of aqueous and alcoholic extract as well as lyophilized powder showed a reduction in blood glucose level^[45]. Hence, treatment with herbal drugs has an effect on protecting β -cells and smoothing out fluctuation in glucose levels^[46,47].

Studies were conducted earlier with polyherbal formulations with varying contents and compositions for their antihyperglycemic potential. A polyherbal formulation, Dihar^[18], containing eight different herbs, *Syzygium cumini*, *Momordica charantia*, *Emblia officinalis*, *Gymnema sylvestre*, *Enicostemma*, *Azadirachta indica*, *Tinospora cordifolia* and *Curcuma longa*^[18], showed effective antihyperglycemic activity in streptozotocin (STZ, 45 mg/kg *iv* single dose) induced diabetes in rats. A polyherbal formulation, termed DRF/AY/5001, containing *Gymnema sylvestre*, *Syzygium cumini*, *Pterocarpus marsupium*, *Momordica charantia*, *Emblia officinalis*, *Terminalia belirica*, *Terminalia chebula* and *Shudh shi-*

lajit, showed an antihyperglycemic effect similar to Glibanclamide^[48]. Similarly, a polyherbal formulation, namely "Diabegon", containing *Gymnema sylvestre*, *Pterocarpus marsupium*, *Glycyrrhiza glabra*, *Casearia esculenta*, *Syzygium cumini*, *Asparagus racemosus*, *Boerhavia diffusa*, *Sphaeranthus indicus*, *Tinospora cordifolia*, *Swertia chirata*, *Tribulus terrestris*, *Phyllanthus amarus*, *Gmelina arborea*, *Gossypium herbaceum*, *Berberis aristata*, *Aloe vera*, *Triphala*, *Commiphora wightii*, *shilajeet*, *Momordica charantia*, *Piper nigrum*, *Ocimum sanctum*, *Abutilon indicum*, *Curcuma longa* and *Rumex maritimus*, is reported to increase peripheral utilization of glucose, increase hepatic and muscle glucagon contents, promote B-cells repair and regeneration, and increase C-peptide level. It exhibited antioxidant properties and protected β -cells from oxidative stress. "Glyoherb" granules were shown to possess potential antidiabetic activity, lowered serum glucose levels and increased glucose tolerance in STZ-induced type 1 diabetic rats. This polyherbal formulation also possesses significant antihyperlipidemic activity as it lowered serum cholesterol and triglyceride levels. "Glyoherb" did not exert any toxic effects in STZ-induced impaired kidney and liver functions. It was found rather to improve kidney and liver functions. In addition, "Glyoherb" possesses potential antioxidant activity as it decreases lipid peroxidation and enhances antioxidant status in diabetic rats^[49,50] and it was reported that the treatment with *Coccinia cordifolia* extract of newly detected type 2 diabetic patients for 90 d results in a 16% decrease in fasting blood glucose level and 18% in PP blood glucose level. Several studies of medicinal plants claimed to have a significant reduction in blood glucose level but in the present study, HbA1C percentage was significantly decreased in type II diabetes subjects after 6 mo of treatment, suggesting that there is a reduction of generalized glycosylation of proteins in circulation. A significant reduction in glycosuria and proteinuria was observed in type II diabetic subjects on "Diabegon kwath" therapy.

Oxidative stress plays a major role in the pathogenesis of both types of diabetes mellitus. Free radical production caused by hyperglycemia may occur by at least three different routes: nonenzymatic glycation^[51], auto-oxidation of glucose and intracellular activation of the polyol pathway^[52,53]. High levels of free radicals and simultaneously declined antioxidant enzyme levels lead to cell damage, inactivation of enzymes and lipid peroxidation. The "Diabegon kwath" in the present study also exhibited potent antioxidant activity, as evident from restoration of the activities of antioxidant enzymatic activities studied. The *Emblia officinalis* which is a rich source of vitamin C has been reported to reduce lipidemia and free radical production in experimental animals, considered to be the most important causative factors for diabetes-related complications. The *E. officinalis* and its enriched tannoids delay diabetic cataract in rats^[54]. The lipid levels, such as cholesterol and triglycerides, in serum and liver were markedly elevated in aged control rats, while they were significantly decreased by the administration of amla^[55]. There is an increased quest to obtain natural antioxidants

with broad spectrum actions. The herbal formulation used in the present study shows significant improvement in markers of oxidative stress, besides antihyperglycemic and antihyperlipidemic functions. Furthermore, oral administration of "Diabegon kwath" daily for 6 mo had no adverse effects, either on kidney or liver functions and in fact a marked improvement in functioning of these vital organs was noticed.

In conclusion, the present study with "Diabegon kwath" in type II diabetic subjects with varying degrees of hyperglycemia, hyperlipidemia and oxidative stress proved that the formulation serves as an effective alternative to conventional antidiabetic therapies. Furthermore, the formulation was found to improve liver and kidney functions and may be regarded as a promising natural and safe remedy for the prevention of diabetic complications. This is the first long term study with any polyherbal formulation in human type II diabetes mellitus.

ACKNOWLEDGMENTS

We thank Deendayal Aushadhi Pvt. Ltd., Gwalior (M.P.) for the supply of the polyherbal formulation and the financial support from AYUSH, New Delhi, is duly acknowledged. We are grateful to all the human subjects who volunteered to participate in the study. Our profound thanks are due to Dr. Mohit Tiwari, Dr. Sheetal Gupta of M/S Deendayal Aushadhi Pvt. Ltd., Gwalior, Sri Dinesh Borole, other colleagues of the laboratory and students for their unreserved support in conducting this study.

COMMENTS

Background

Type 2 diabetes is a multifaceted lifelong disorder and can lead to micro and macrovascular complications when left unchecked. The oral hypoglycemic agents available for the treatment of type II diabetes mellitus are reported to exhibit undesired side effects in a considerable number of subjects, even under euglycemic conditions. Polyherbal preparations are shown to function as potential antihyperglycemic agents.

Research frontiers

Polyherbal based Ayurvedic formulations are in regular use in southeastern countries as drug supplements for the treatment of type II diabetes mellitus. Scientific validation of such preparations and their safety evaluations are major concerns to biomedical scientists working on indigenous systems of medicine.

Innovations and breakthroughs

Several short term studies in experimental models revealed antidiabetic potentials of many polyherbal based formulations and very few herbal drug preparations have succeeded in human trials. This is the first ever long term open study validating an antidiabetic Ayurvedic formulation in human type II diabetes mellitus. The study not only evaluated the efficacy of the Ayurvedic polyherbal formulation but also addressed the safety concerns in human subjects.

Applications

The study revealed that "Diabegon kwath" functions as an effective alternative antidiabetic drug formulation which can safely be advocated for treatment of human type 2 diabetes mellitus.

Terminology

"Diabegon kwath" is a hot water extract of defined plant/herb parts.

Peer review

The study is interesting and not well known in the majority of countries. This is a long term study about the efficacy of "Diabegon kwath", a polyherbal for-

mulation with diverse therapeutic functions. The formulation acts on glucose metabolism, lipids and functions as an antioxidant and the results of the study are significant.

REFERENCES

- 1 **American Diabetes Association.** Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2011; **34** Suppl 1: S62-S69 [PMID: 21193628 DOI: 10.2337/dc11-S062]
- 2 **Hamamdzc D, Wilensky RL.** Porcine models of accelerated coronary atherosclerosis: role of diabetes mellitus and hypercholesterolemia. *J Diabetes Res* 2013; **2013**: 761415 [PMID: 23844374 DOI: 10.1155/2013/761415]
- 3 **Michael J, Fowler MD.** Diabetes Treatment, Part 2: Oral agents for glycemic management. *Clin Diabetes* 2007; **25**: 131-134 [DOI: 10.2337/diaclin.25.4.131]
- 4 **Wang L, Duan G, Lu Y, Pang S, Huang X, Jiang Q, Dang N.** The effect of simvastatin on glucose homeostasis in streptozotocin induced type 2 diabetic rats. *J Diabetes Res* 2013; **2013**: 274986 [PMID: 23671864 DOI: 10.1155/2013/274986]
- 5 **Salimifar M, Fatehi-Hassanabad Z, Fatehi M.** A review on natural products for controlling type 2 diabetes with an emphasis on their mechanisms of actions. *Curr Diabetes Rev* 2013; **9**: 402-411 [PMID: 23865416 DOI: 10.2174/15733998113099990076]
- 6 **Chang CL, Lin Y, Bartolome AP, Chen YC, Chiu SC, Yang WC.** Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. *Evid Based Complement Alternat Med* 2013; **2013**: 378657 [PMID: 23662132 DOI: 10.4103/0974-8490.105644]
- 7 **Ocvirk S, Kistler M, Khan S, Talukder SH, Hauner H.** Traditional medicinal plants used for the treatment of diabetes in rural and urban areas of Dhaka, Bangladesh—an ethnobotanical survey. *J Ethnobiol Ethnomed* 2013; **9**: 43 [PMID: 23800215 DOI: 10.1186/1746-4269-9-43]
- 8 **Kalekar SA, Munshi RP, Bhalerao SS, Thatte UM.** Insulin sensitizing effect of 3 Indian medicinal plants: an in vitro study. *Indian J Pharmacol* 2013; **45**: 30-33 [PMID: 23543787 DOI: 10.4103/0253-7613.106431]
- 9 **Jarouliya U, Zacharia JA, Kumar P, Bisen PS, Prasad GB.** Alleviation of metabolic abnormalities induced by excessive fructose administration in Wistar rats by *Spirulina maxima*. *Indian J Med Res* 2012; **135**: 422-428 [PMID: 22561632]
- 10 **Marzouk M, Soliman AM, Omar TY.** Hypoglycemic and antioxidative effects of fenugreek and termis seeds powder in streptozotocin-diabetic rats. *Eur Rev Med Pharmacol Sci* 2013; **17**: 559-565 [PMID: 23467959]
- 11 **Meng HC, Wang S, Li Y, Kuang YY, Ma CM.** Chemical constituents and pharmacologic actions of *Cynomorium* plants. *Chin J Nat Med* 2013; **11**: 321-329 [PMID: 23845540 DOI: 10.1016/S1875-5364(13)]
- 12 **Salib JY, Michael HN, Eskande EF.** Anti-diabetic properties of flavonoid compounds isolated from *Hyphaene thebaica* epicarp on alloxan induced diabetic rats. *Pharmacognosy Res* 2013; **5**: 22-29 [PMID: 23598921]
- 13 **Grover JK, Vats V, Rathi SS.** Anti-hyperglycemic effect of *Eugenia jambolana* and *Tinospora cordifolia* in experimental diabetes and their effects on key metabolic enzymes involved in carbohydrate metabolism. *J Ethnopharmacol* 2000; **73**: 461-470 [PMID: 11091000 DOI: 10.1016/S0378-8741(00)00319-6]
- 14 **Pari L, Saravanan G.** Antidiabetic effect of Cogent db, a herbal drug in alloxan-induced diabetes mellitus. *Comp Biochem Physiol C Toxicol Pharmacol* 2002; **131**: 19-25 [PMID: 11796322 DOI: 10.1016/S1532-0456(01)00259-9]
- 15 **El-Sayyad HL, El-Sherbiny MA, Sobh MA, Abou-El-Naga AM, Ibrahim MA, Mousa SA.** Protective effects of *Morus alba* leaves extract on ocular functions of pups from diabetic and hypercholesterolemic mother rats. *Int J Biol Sci* 2011; **7**: 715-728 [PMID: 21697998 DOI: 10.7150/ijbs.7.715]
- 16 **Mitra SK, Gopumadhavan S, Muralidhar TS, Anturlikar SD,**

- Sujatha MB. Effect of a herbomineral preparation D-400 in streptozotocin-induced diabetic rats. *J Ethnopharmacol* 1996; **54**: 41-46 [PMID: 8941867 DOI: 10.1016/0378-8741(96)01439-0]
- 17 **Pari L**, Ramakrishnan R, Venkateswaran S. Antihyperglycaemic effect of Diamed, a herbal formulation, in experimental diabetes in rats. *J Pharm Pharmacol* 2001; **53**: 1139-1143 [PMID: 11518024 DOI: 10.1211/0022357011776397]
- 18 **Patel SS**, Shah RS, Goyal RK. Antihyperglycemic, antihyperlipidemic and antioxidant effects of Dihar, a polyherbal ayurvedic formulation in streptozotocin induced diabetic rats. *Indian J Exp Biol* 2009; **47**: 564-570 [PMID: 19761040]
- 19 **Raabo E**, TERKILDSEN TC. On the enzymatic determination of blood glucose. *Scand J Clin Lab Invest* 1960; **12**: 402-407 [PMID: 13738785 DOI: 10.3109/00365516009065404]
- 20 **Trivelli LA**, Ranney HM, Lai HT. Hemoglobin components in patients with diabetes mellitus. *N Engl J Med* 1971; **284**: 353-357 [PMID: 5539916 DOI: 10.1056/NEJM197102182840703]
- 21 **Stockbridge H**, Hardy RI, Glueck CJ. Public cholesterol screening: motivation for participation, follow-up outcome, self-knowledge, and coronary heart disease risk factor intervention. *J Lab Clin Med* 1989; **114**: 142-151 [PMID: 2754303]
- 22 **Fossati P**, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. *Clin Chem* 1982; **28**: 2077-2080 [PMID: 6812986]
- 23 **Lopes-Virella MF**, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. *Clin Chem* 1977; **23**: 882-884 [PMID: 192488]
- 24 **Fawcett JK**, Scott JE. A rapid and precise method for the determination of urea. *J Clin Pathol* 1960; **13**: 156-159 [PMID: 13821779 DOI: 10.1136/jcp.13.2.156]
- 25 **Fossati P**, Prencipe L, Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. *Clin Chem* 1980; **26**: 227-231 [PMID: 7353268]
- 26 **Bowers LD**, Wong ET. Kinetic serum creatinine assays. II. A critical evaluation and review. *Clin Chem* 1980; **26**: 555-561 [PMID: 7020989]
- 27 **Reitman S**, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am J Clin Pathol* 1957; **28**: 56-63 [PMID: 13458125]
- 28 **Jendrassik L**, Grof P. Simplified photometric methods for the determination of the blood bilirubin. *Biochemistry* 1938; **297**: 81-89
- 29 **Winterbourn CC**, Hawkins RE, Brian M, Carrell RW. The estimation of red cell superoxide dismutase activity. *J Lab Clin Med* 1975; **85**: 337-341 [PMID: 803541]
- 30 **Sinha AK**. Colorimetric assay of catalase. *Anal Biochem* 1972; **47**: 389-394 [PMID: 4556490 DOI: 10.1016/0003-2697(72)90132-7]
- 31 **Ellman GL**. Tissue sulfhydryl groups. *Arch Biochem Biophys* 1959; **82**: 70-77 [PMID: 13650640 DOI: 10.1016/0003-9861(59)90090-6]
- 32 **Ohkawa H**, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem* 1979; **95**: 351-358 [PMID: 36810 DOI: 10.1016/0003-2697(79)90738-3]
- 33 **Lowry OH**, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951; **193**: 265-275 [PMID: 14907713]
- 34 **Sur BK**, Shukla RK, Agashe VS. The role of creatinine and histidine in Benedict's qualitative test for reducing sugar in urine. *J Clin Pathol* 1972; **25**: 892-895 [PMID: 4646301 DOI: 10.1136/jcp.25.10.892]
- 35 **Wians FH**, Jenkins GL, Staples N, Heald JI. Quantification of urinary albumin and globulin by the sulfosalicylic acid/trichloroacetic acid and DuPont "aca III" analyzer turbidimetric total protein methods. *Clin Chem* 1988; **34**: 424-425 [PMID: 3342523]
- 36 **Baskaran K**, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER. Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. *J Ethnopharmacol* 1990; **30**: 295-300 [PMID: 2259217 DOI: 10.1016/0378-8741(90)90108-6]
- 37 **Persaud SJ**, Al-Majed H, Raman A, Jones PM. *Gymnema sylvestre* stimulates insulin release in vitro by increased membrane permeability. *J Endocrinol* 1999; **163**: 207-212 [PMID: 10556769 DOI: 10.1677/joe.0.1630207]
- 38 **Raman A**, Lau C. Anti-diabetic properties and phytochemistry of *Momordica charantia* L. (Cucurbitaceae). *Phytochemistry* 1996; **2**: 349-362 [PMID: 23194773 DOI: 10.1016/S0944-7113(96)80080-8.]
- 39 **Lodha R**, Bagga A. Traditional Indian systems of medicine. *Ann Acad Med Singapore* 2000; **29**: 37-41 [PMID: 10748962]
- 40 **Joy KL**, Kuttan R. Anti-diabetic activity of *Picrorrhiza kurroa* extract. *J Ethnopharmacol* 1999; **67**: 143-148 [PMID: 10619377 DOI: 10.1016/S0378-8741(98)00243-8]
- 41 **Bnouham M**, Ziyat A, Mekhfi H, Tahri A, Legssyer A. Medicinal plants with potential antidiabetic activity-a review of ten years of herbal medicine research (1990-2000). *Int J Diabetes Metab* 2006; **14**: 1-25. Available from: URL: http://ijod.uaeu.ac.ae/iss_1401/a.pdf
- 42 **Ratnasooriya WD**, Hettiarachchi HDI, Jayakody JRAC. Cassia fistula and hypoglycemia. *Aust J Med Herbalism* 2004; **16**: 8-14. Available from: URL: <http://archive.cmb.ac.lk/research/bitstream/70130/2158/1/profR084.pdf>
- 43 **Silawat N**, Edwin JE, Jain N, Yadav A, Deshmukh TP. The mechanism of hypoglycemic and antidiabetic action of hydro alcoholic extract of *Cassia fistula* Linn. In rats. *J of Pharm Research* 2009; **1**: 82-92. Available from: URL: <http://www.thepharmaresearch.info/documents/PDF/TPR-090110.pdf>
- 44 **Cheng HY**, Lin TC, Yu KH, Yang CM, Lin CC. Antioxidant and free radical scavenging activities of *Terminalia chebula*. *Biol Pharm Bull* 2003; **26**: 1331-1335 [PMID: 12951481 DOI: 10.1248/bpb.26.1331]
- 45 **Vats V**, Yadav SP, Grover JK. Ethanolic extract of *Ocimum sanctum* leaves partially attenuates streptozotocin-induced alterations in glycogen content and carbohydrate metabolism in rats. *J Ethnopharmacol* 2004; **90**: 155-160 [PMID: 14698524 DOI: 10.1016/j.jep.2003.09.034]
- 46 **Jia W**, Gao WY, Xiao PG. Antidiabetic drugs of plant origin used in China: compositions, pharmacology, and hypoglycemic mechanisms. *Zhongguo Zhongyao Zazhi* 2003; **28**: 108-113 [PMID: 15015278]
- 47 **Elder C**. Ayurveda for diabetes mellitus: a review of the biomedical literature. *Altern Ther Health Med* 2004; **10**: 44-50 [PMID: 14727499]
- 48 **Mandlik RV**, Desai SK, Naik SR, Sharma G, Kohli RK. Antidiabetic activity of a polyherbal formulation (DRF/AY/5001). *Indian J Exp Biol* 2008; **46**: 599-606 [PMID: 18814489]
- 49 **Thakkar NV**, Patel JA. Pharmacological evaluation of "Glyoherb": A polyherbal formulation on streptozotocin-induced diabetic rats. *Int J Diabetes Dev Ctries* 2010; **30**: 1-7 [PMID: 20431798 DOI: 10.4103/0973-3930.60001]
- 50 **Sahana DA**, Shivaprakash G, Baliga R, Adhikari Prabha MR, Ganesh J, Pai MRSM. Effect of *Eugenia jambolana* on Plasma Glucose, Insulin Sensitivity and HDL-C Levels: Preliminary results of a randomized clinical trial. *J Pharmacy Res* 2010; **3**: 1268-1270. Available from: URL: <http://www.jpronline.info>
- 51 **Ceriello A**, Quatraro A, Giugliano D. New insights on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. *Diabet Med* 1992; **9**: 297-299 [PMID: 1576819 DOI: 10.1111/j.1464-5491.1992.tb01783.x]
- 52 **Wolff SP**, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. *Biochem J* 1987; **245**: 243-250 [PMID: 3117042]

- 53 **Ceriello A.** Oxidative stress and glycemc regulation. *Metabolism* 2000; **49**: 27-29 [PMID: 10693917 DOI: 10.1016/S0026-0495(00)80082-7]
- 54 **Suryanarayana P,** Saraswat M, Petrash JM, Reddy GB. Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. *Mol Vis* 2007; **13**: 1291-1297 [PMID: 17679931]
- 55 **Yokozawa T,** Cho EJ, Sasaki S, Satoh A, Okamoto T, Sei Y. The protective role of Chinese prescription Kangen-karyu extract on diet-induced hypercholesterolemia in rats. *Biol Pharm Bull* 2006; **29**: 760-765 [PMID: 16595914 DOI: 10.1248/bpb.29.760]

P- Reviewers: Ali O, Gómez-Sáez J, Teanpaisan R
S- Editor: Song XX **L- Editor:** Roemmele A **E- Editor:** Wu HL





百世登

Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-31158812

Telephone: +852-58042046

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

